http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AbbVie's Research in Immunology to be Featured at the European League Against Rheumatism Annual Congress (EULAR) 2015
-
Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Publishe
-
AbbVie to Present at Jefferies 2015 Healthcare Conference
-
AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting
-
AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting
-
AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis
-
AbbVie Completes Acquisition of Pharmacyclics
-
AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics
-
AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics
-
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
-
AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS)
-
AbbVie to Present at UBS Global Healthcare Conference
-
AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015
-
AbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the 51st American Society of Clinical Oncology Annual Meeting
-
Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutati
-
AbbVie to Present at Bank of America Merrill Lynch 2015 Health Care Conference
-
AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy and Safety of HUMIRA® (adalimumab) in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis
-
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
-
AbbVie to Present at Deutsche Bank 40th Annual Health Care Conference
-
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
-
AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015
-
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C
-
AbbVie Reports First-Quarter 2015 Financial Results
-
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
-
AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan
-
AbbVie to Host First-Quarter Earnings Conference Call
-
AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015
-
AbbVie CF Scholarship Application for Students with Cystic Fibrosis Now Available for 2015-2016 Academic School Year
-
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS
-
AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy
-
AbbVie's Dermatology Leadership Showcased with HUMIRA® (adalimumab) Data at American Academy of Dermatology 2015 Annual Meeting
-
AbbVie to Present at Barclays Global Health Care Conference
-
Streetinsider.com's Hot Lunchtime Reads 2/9: (AMD) (TWTR) (KORS) (GOOG)
-
Notable Analyst Rating Changes 10/21: (GPOR) (ILMN) (POST) Upgraded; (ABBV) (IBM) (BHP) Downgraded
-
FTC Files Complaint Against AbbVie (ABBV), Besins Over Delays to Generic AndroGel
-
Notable Mergers and Acquisitions of the Day 07/18: (GTIV) (ABBV)/(SHPG) (TWTR) (RDNT)
-
Notable 52-Week Highs and Lows of the Day 12/10: (CIM) (TWTR) (CVS) High; (BURL) (EW) (FIO) Low

